{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:44:55Z","timestamp":1794368695808,"version":"4.9.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1136\/ijgc-2019-001109","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T12:49:36Z","timestamp":1591879776000},"page":"1034-1042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer"],"prefix":"10.1016","volume":"30","author":[{"given":"Estrid","family":"H\u00f8gdall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"H\u00f8gdall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingkang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Marton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M","family":"Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Busch-S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Georgsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else","family":"Mejlgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte","family":"Nedergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Steiniche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2019-001109_bb0010","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2019-001109_bb0015","first-page":"937","article-title":"Diagnosis and management of ovarian cancer","volume":"93","author":"Doubeni","year":"2016","journal-title":"Am Fam Physician"},{"key":"10.1136\/ijgc-2019-001109_bb0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.intimp.2017.08.017","article-title":"Prognostic value of tumor PD-L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer","volume":"52","author":"Wang","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"10.1136\/ijgc-2019-001109_bb0025","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1136\/ijgc-2019-001109_bb0030","doi-asserted-by":"crossref","DOI":"10.1186\/s40661-016-0033-6","article-title":"The role of immune checkpoint inhibition in the treatment of ovarian cancer","volume":"3","author":"Gaillard","year":"2016","journal-title":"Gynecol Oncol Res Pract"},{"key":"10.1136\/ijgc-2019-001109_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17071169","article-title":"Immune checkpoint inhibitors: a new opportunity in the treatment of ovarian cancer?","volume":"17","author":"Mittica","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1136\/ijgc-2019-001109_bb0040","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2017.28.e77","article-title":"Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma","volume":"28","author":"Zhu","year":"2017","journal-title":"J Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-001109_bb0045","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ijgc-2019-001109_bb0050","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","article-title":"PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer","volume":"141","author":"Webb","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-001109_bb0055","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.18632\/oncotarget.6429","article-title":"Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma","volume":"7","author":"Darb-Esfahani","year":"2016","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2019-001109_bb0060","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1136\/ijgc-2019-001109_bb0065","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.tranon.2016.01.003","article-title":"PD-L1 expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy","volume":"9","author":"Sorensen","year":"2016","journal-title":"Transl Oncol"},{"key":"10.1136\/ijgc-2019-001109_bb0070","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0367-1","article-title":"Pan-cancer adaptive immune resistance as defined by the tumor inflammation signature (TIS): results from the cancer genome atlas (TCGA)","volume":"6","author":"Danaher","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1136\/ijgc-2019-001109_bb0075","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3034","article-title":"Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx analysis system","volume":"34","author":"Wallden","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-001109_bb0080","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.21037\/tcr.2018.10.11","article-title":"Characterization of PD-L1 expression and its prognostic value in patients with ovarian cancer","volume":"7","author":"Cheng","year":"2018","journal-title":"Transl Cancer Res"},{"key":"10.1136\/ijgc-2019-001109_bb0085","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-018-0414-z","article-title":"Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand-1 (PD-L1) in ovarian cancer","volume":"11","author":"Drakes","year":"2018","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2019-001109_bb0090","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00428-019-02528-6","article-title":"Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK\/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma","volume":"474","author":"Schmoeckel","year":"2019","journal-title":"Virchows Arch"},{"key":"10.1136\/ijgc-2019-001109_bb0095","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.3892\/ol.2016.4301","article-title":"Clinical relevance of expression of B7-H1 and B7-H4 in ovarian cancer","volume":"11","author":"Xu","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1136\/ijgc-2019-001109_bb0100","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ygyno.2018.08.023","article-title":"Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer","volume":"151","author":"Kim","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-001109_bb0105","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2017.0013","article-title":"A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer","volume":"3","author":"Rimm","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2019-001109_bb0110","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1136\/ijgc-2019-001109_bb0115","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy287.007","article-title":"Comparison of patient populations identified by different PD-L1 assays in head and neck squamous cell carcinoma (HNSCC)","volume":"29","author":"Scott","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2019-001109_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009615","article-title":"Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets","volume":"5","author":"Yoshihara","year":"2010","journal-title":"PLoS One"},{"key":"10.1136\/ijgc-2019-001109_bb0125","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-001109_bb0130","doi-asserted-by":"crossref","first-page":"viii219","DOI":"10.1093\/annonc\/mdy282.037","article-title":"PD-L1 expression and T-cell inflamed gene expression profile (GEP) in Korean and US patients (pts) with advanced gastric cancer (GC)","volume":"29","author":"Rha","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2019-001109_bb0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2019-001109_bb0140","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2019-001109_bb0145","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/bjc.2011.328","article-title":"Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort","volume":"105","author":"Zang","year":"2011","journal-title":"Br J Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24001749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24001749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2019-001109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:25:36Z","timestamp":1753233936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24001749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1048891X24001749"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2019-001109","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2019-001109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}